FDA Detects Hidden Prescription Ingredients in Over-the-Counter Male Sexual Enhancement Products

FDA Detects Hidden Prescription Ingredients in Over-the-Counter Male Sexual Enhancement Products

The U.S. Food and Drug Administration issued a public notification on September 12, 2024, reporting that laboratory analysis identified undeclared sildenafil or tadalafil in certain male sexual enhancement products sold over the counter. These ingredients are PDE5 inhibitors used in FDA-approved prescription drugs for erectile dysfunction. The agency stated that the hidden substances can produce serious adverse effects, including hypotension when taken with nitrates present in medications prescribed for diabetes or heart conditions. The alert forms part of the FDA’s cumulative monitoring of adulterated sexual enhancement supplements.

What this means

The notification updates the FDA’s running list of implicated brands and confirms that new instances of adulteration continue to appear in the male enhancement category. It illustrates the gap between dietary supplement marketing and federal oversight, as these products reach consumers before post-market testing identifies the presence of prescription ingredients. The findings align with prior FDA documentation showing repeated detection of similar undeclared PDE5 inhibitors.

FDA Alert Details

The FDA’s September 12, 2024 safety alert lists specific male enhancement products in which laboratory testing detected hidden sildenafil or tadalafil or their analogs. [1] The agency published the findings on its recalls and safety alerts portal together with product images and lot information where available.

Ingredients Detected and Documented Risks

Laboratory results confirmed the presence of undeclared PDE5 inhibitors that match active pharmaceutical ingredients in approved erectile dysfunction drugs. [2] The FDA safety alert links these substances to clinically significant drops in blood pressure when combined with nitrates, a class of medications frequently prescribed for cardiovascular disease and diabetes. [1]

Regulatory Framework

Dietary supplements do not require premarket FDA approval. [3] The National Institutes of Health notes that federal oversight instead depends on post-market surveillance to detect adulteration after products have entered commercial distribution. This structure was summarized in NIH regulatory overviews updated as of November 2023. [3]

Continuity with Previous FDA Communications

The September 2024 alert adds to an established FDA database that has documented dozens of tainted sexual enhancement products over multiple years. [2] Agency records show that male enhancement supplements remain a category in which hidden PDE5 inhibitors recur despite earlier public notifications.

Limitations

FDA testing covers only a sample of available products; the full scope of adulterated supplements on the market is unknown. Adverse event data relies on voluntary reporting and may underrepresent incidence. Long-term population-level outcomes of intermittent exposure to these hidden ingredients are not fully characterized in peer-reviewed literature.